My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

The Latest Analyst Ratings for Sage Therapeutics ↗

October 13, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 08, 2023

Via Benzinga

Where Sage Therapeutics Stands With Analysts ↗

September 07, 2023

Via Benzinga

3 Healthcare Stocks to Sell in September Before They Crash & Burn ↗

September 06, 2023

The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.

Via InvestorPlace

Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment ↗

August 31, 2023

The company is now focusing on its launch in postpartum depression.

Via Investor's Business Daily

3 Very Oversold Pharma Stocks to Buy Right Now ↗

August 24, 2023

Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy.

Via InvestorPlace

Is Sage Therapeutics a Contrarian Buy? ↗

August 08, 2023

A regulatory setback weighed heavily on the drugmaker's shares Monday.

Via The Motley Fool

Why Sage Therapeutics Stock Is Crashing Today ↗

August 07, 2023

Sage's regulatory win wasn't enough to offset an even bigger regulatory loss.

Via The Motley Fool

Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? ↗

August 24, 2023

The pharmaceutical company's growth prospects have taken a big hit.

Via The Motley Fool

Why Shares of Sage Therapeutics Slumped This Week ↗

August 11, 2023

The company got bad news from the FDA and saw increased losses.

Via The Motley Fool

Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday ↗

August 11, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

August 11, 2023

These companies aren't bargains at all.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗

August 08, 2023

Via Benzinga

Market Volatility Falls Sharply, S&P 500 Snaps 4-Session Losing Streak ↗

August 08, 2023

The S&P 500 settled higher on Monday, snapping a four-session losing streak. U.S. stocks have notched sharp gains this year, with the benchmark S&P 500 adding around 17.7% in 2023. As far as the...

Via Benzinga

Dow Gains 1%; Tabula Rasa HealthCare Shares Spike Higher ↗

August 07, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P...

Via Benzinga

What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead ↗

August 07, 2023

The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 07, 2023

Via Benzinga

Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 07, 2023

Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...

Via Benzinga

Dow Rises Over 300 Points To Start The Week ↗

August 07, 2023

The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses.

Via Talk Markets

FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗

August 07, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.

Via Benzinga

Crude Oil Down Over 1%; Henry Schein Earnings Top Views ↗

August 07, 2023

U.S. stocks were higher midway through trading, with the Dow Jones gaining more than 300 points on Monday. The Dow traded up 0.88% to 35,374.41 while the NASDAQ rose 0.12% to 13,925.71. The S&P 500,...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 7, 2023 ↗

August 07, 2023

Via Benzinga

PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories ↗

August 07, 2023

Benzinga

Via Benzinga

Why Sage Therapeutics Shares Are Sinking Monday ↗

August 07, 2023

Sage Therapeutics Inc (NASDAQ: SAGE) shares are trading lower Monday after the company announced the FDA issued a Complete Response Letter (CRL) for one of the company's

Via Benzinga

SOVO Stock Alert: Campbell Soup Is Buying Sovos Brands for $2.7 Billion ↗

August 07, 2023

Sovos Brands (SOVO) stock is rising higher on Monday following news that Campbell Soup (CPB) is acquiring the Italian sauces company.

Via InvestorPlace

Dow Jumps 250 Points; Tyson Foods Posts Downbeat Results ↗

August 07, 2023

U.S. stocks were higher this morning, with the Dow Jones gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.77% to 35,334.81 while the NASDAQ rose 0.42% to...

Via Benzinga

Why Is Sage Therapeutics (SAGE) Stock Down 48% Today? ↗

August 07, 2023

Sage Therapeutics (SAGE) stock isn't doing the best on Monday after the FDA weighed in on the company's depression drug zuranolone.

Via InvestorPlace

Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug ↗

August 07, 2023

The company gained approval for the first oral treatment for postpartum depression.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 07, 2023

Via Benzinga

FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another ↗

August 07, 2023

The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.